I.v

Altered lung function/PFTs (can be subclinical)

(Fr: Sd restrictif ou altération de la diffusion isolés). Change in static or dynamic volumes or flows, diffusion for CO, compliance, ABG or distribution of ventilation. Pulmonary function tests (PFTs) may show a restrictive lung function defect or a lowtrending diffusing capacity for CO without necessarily the presence of clinical symptoms or definite changes on imaging including HRCT. Changes in PFT may develop concomitant with the administration of the causal drug or drugs, or they are noted as a persistent late finding upon termination of treatment or as a slowly progressive drift that needs be followed-up. These findings may reflect incipient or rampant subclinical ILD or pulmonary fibrosis, bronchiolitis obliterans, pulmonary hypertension or pleural fibrosis

Last update : 01/01/1970
 

Causative drugs

27

Bleomycin

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified)
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.p I - Interstitial/parenchymal lung disease
I.p - Fatal pneumonitis (ILD)
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.p V - Pleural and/or pericardial involvement
V.p - Pleuroparenchymal fibroelastosis (PPFE)
V.z V - Pleural and/or pericardial involvement
V.z - Pneumothorax (secondary to drug-induced ILD)
VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease
VI.f VI - Pulmonary vasculopathies
VI.f - Hemolytic and uremic syndrome (HUS). See also under Xaf
VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy
VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain (see also under Vi)
XV.a XV - Pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.h XV - Pathology
XV.h - Path: Fibrotic NSIP pattern
XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells)
XV.j XV - Pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern)
XV.ax XV - Pathology
XV.ax - Path: Focal organizing pneumonia
XV.be XV - Pathology
XV.be - Path: Interstitial pulmonary edema
XV.bf XV - Pathology
XV.bf - Path: Pulmonary necrotizing granuloma or granulomas
XVI.a XVI - Imaging
XVI.a - Imaging: Diffuse haze
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing
XVI.e XVI - Imaging
XVI.e - Imaging: Pulmonary opacities with a subpleural distribution
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVI.w XVI - Imaging
XVI.w - Imaging: Lung nodule or nodules
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodule or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf)
XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the chest on 18F-PET scan
XVIII.j XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.j - Eye-catcher: Avid lung uptake on PET-CT
XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
XXIV.a XXIV - Veterinary medicine
XXIV.a - Veterinary: Pneumonitis - Interstitial lung disease
XXIV.b XXIV - Veterinary medicine
XXIV.b - Veterinary: Pulmonary fibrosis
3

Busulfan

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified)
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP)
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
XV.a XV - Pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.h XV - Pathology
XV.h - Path: Fibrotic NSIP pattern
XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells)
XV.n XV - Pathology
XV.n - Path: Pulmonary alveolar proteinosis pattern (PAP pattern)
XV.bc XV - Pathology
XV.bc - Path: Opportunistic pulmonary infection (see also XVII/XVIIb-d-e)
XVI.d XVI - Imaging
XVI.d - Imaging: Alveolar opacities or haze with a batwing or butterfly distribution
XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary
1

Chemotherapy, antineoplastic

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified)
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP)
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)
I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis
I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis
I.au I - Interstitial/parenchymal lung disease
I.au - Chemotherapy lung - The chemotherapy lung
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.c II - Pulmonary edema - Acute lung injury - ARDS
II.c - ARDS and the hemolytic-uremic syndrome (HUS)
II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic
III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
IV.k IV - Airway involvement
IV.k - Bronchiectasis
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.ab V - Pleural and/or pericardial involvement
V.ab - Pneumothorax, bilateral
VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension
VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease
VI.f VI - Pulmonary vasculopathies
VI.f - Hemolytic and uremic syndrome (HUS). See also under Xaf
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum
VIII.a VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death)
IX.f IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.f - Hiccup
IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis
IX.o IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.o - Pneumorachis
X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS)
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis
X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reactions (may involve skin, throat and/or airways)
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia/infarction - Coronary artery disease, acute
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Conduction disorders - Heart block (bundle branch- or AV-)
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - 'Cardiotoxicity'
XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer
XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)
XIII.d XIII - Neoplastic conditions
XIII.d - Malignant mesothelioma (pleural, pericardial)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells)
XV.l XV - Pathology
XV.l - Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)
XV.ak XV - Pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD)
XV.am XV - Pathology
XV.am - Path: Thrombosis in pulmonary arterioles/venules
XV.ba XV - Pathology
XV.ba - Path: Granulomatous lymphadenopathy
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodule or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf)
XVI.bf XVI - Imaging
XVI.bf - Imaging: Tumoral cavitation
XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the chest on 18F-PET scan
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.j XVII - Infections & related conditions
XVII.j - Mucormycosis (pulmonary, tracheobronchial or systemic)
XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary)
XVII.af XVII - Infections & related conditions
XVII.af - Reactivation of a prior pulmonary infection (TB, melioidosis)
4

E-cigarette - e-vaporizers-ENDS-Vaping-Dabbing

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.j I - Interstitial/parenchymal lung disease
I.j - Lipoid pneumonia, exogenous
I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id)
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH)
III.c III - Pulmonary/alveolar hemorrhage
III.c - Hemoptysis
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc)
IV.t IV - Airway involvement
IV.t - Bronchitis, chronic bronchitis, bronchorrhea
IV.v IV - Airway involvement
IV.v - Deterioration/exacerbation of preexisting asthma or COPD
VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum
VIII.d VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.d - Thermal (burns, frostbite), chemical, or caustic facial and/or airway injury
X.aq X - Systemic/Distant conditions, syndromes and reactions
X.aq - Relapse or flare of preexisting ulcerative colitis
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XI.ac XI - Miscellaneous
XI.ac - Thermal skin/dermal injury
XII.ag XII - Cardiovascular involvement / toxicity
XII.ag - Bradycardia
XIV.a XIV - Hemoglobinopathies - Abnormal hemoglobin states (acquired)
XIV.a - Methemoglobinemia
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.p XV - Pathology
XV.p - Path: Exogenous lipoid pneumonia
XV.x XV - Pathology
XV.x - Path: Acute or subacute bronchiolitis (see also IVc, IVi)
XV.y XV - Pathology
XV.y - Path: Respiratory bronchiolitis (RB-ILD-pattern)
XV.bi XV - Pathology
XV.bi - Path: Giant-cell interstitial pneumonia (GIP)-pattern
XVI.a XVI - Imaging
XVI.a - Imaging: Diffuse haze
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing
XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia
XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
XIX.f XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.f - BAL: Foamy macrophages
XIX.h XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.h - BAL: Exogenous (foreign) lipids in BAL cells
XIX.n XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.n - BAL: Brown-pigmented macrophages
1

Everolimus

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.p I - Interstitial/parenchymal lung disease
I.p - Fatal pneumonitis (ILD)
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH)
III.h III - Pulmonary/alveolar hemorrhage
III.h - Major/massive hemoptysis
IV.d IV - Airway involvement
IV.d - Cough (lone)
V.h V - Pleural and/or pericardial involvement
V.h - Chylothorax
V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (may cause acute chest pain (see also under XIc)
VI.a VI - Pulmonary vasculopathies
VI.a - Venous thrombo-embolism - Pulmonary embolism
VIII.a VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death)
XV.a XV - Pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing
XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the chest on 18F-PET scan
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
2

Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified)
I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id)
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)
I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis
I.aj I - Interstitial/parenchymal lung disease
I.aj - Shrinking lung syndrome
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic
III.m III - Pulmonary/alveolar hemorrhage
III.m - Coagulopathy
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis (may cause neuromuscular ARF)
IX.ab IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ab - Guillain-Barré (or GB-like) syndrome (w/wo ARF)
IX.ac IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ac - Myositis of the respiratory muscles (May lead to respiratory muscle paralysis)
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRESS - DRESS-like reaction
X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS)
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reactions (may involve skin, throat and/or airways)
X.h X - Systemic/Distant conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba)
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.am X - Systemic/Distant conditions, syndromes and reactions
X.am - Immune-related adverse effect/toxicity
X.aw X - Systemic/Distant conditions, syndromes and reactions
X.aw - Connective tissue disease
X.ay X - Systemic/Distant conditions, syndromes and reactions
X.ay - Polymyalgia rheumatica
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XI.y XI - Miscellaneous
XI.y - Adrenal suppression
XI.ag XI - Miscellaneous
XI.ag - Vertebral compression fracture
XI.au XI - Miscellaneous
XI.au - Graft vs. host disease in transplant recipients
XI.av XI - Miscellaneous
XI.av - Deterioration of graft function in SOT recipients
XI.ba XI - Miscellaneous
XI.ba - Nonrespiratory AE of interest
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Conduction disorders - Heart block (bundle branch- or AV-)
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - 'Cardiotoxicity'
XII.ax XII - Cardiovascular involvement / toxicity
XII.ax - Necrotizing myocarditis (w/o evidence for CAD)
XII.ba XII - Cardiovascular involvement / toxicity
XII.ba - Sudden cardiac death
XV.a XV - Pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.l XV - Pathology
XV.l - Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)
XV.ba XV - Pathology
XV.ba - Path: Granulomatous lymphadenopathy
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
1

Interferon alpha/beta

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.w IV - Airway involvement
IV.w - Plugs/casts in the airways
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension
VI.d VI - Pulmonary vasculopathies
VI.d - Pulmonary vasculitis or capillaritis
VI.f VI - Pulmonary vasculopathies
VI.f - Hemolytic and uremic syndrome (HUS). See also under Xaf
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy
VIII.a VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death)
X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS)
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis
X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba)
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XV.a XV - Pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.k XV - Pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern)
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
2

Ipilimumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy
IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis
IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis (may cause neuromuscular ARF)
IX.ab IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ab - Guillain-Barré (or GB-like) syndrome (w/wo ARF)
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRESS - DRESS-like reaction
X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reactions (may involve skin, throat and/or airways)
X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba)
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
X.l X - Systemic/Distant conditions, syndromes and reactions
X.l - Systemic granulomatosis other than Xk
X.o X - Systemic/Distant conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome)
X.am X - Systemic/Distant conditions, syndromes and reactions
X.am - Immune-related adverse effect/toxicity
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XII.az XII - Cardiovascular involvement / toxicity
XII.az - Fulminant myocarditis (See also under XIId)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.ci XV - Pathology
XV.ci - Path: Fibrinous pericarditis
XVI.bh XVI - Imaging
XVI.bh - Imaging: F18-PET scan positive lympadenopathy
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
1

Methotrexate

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified)
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.q I - Interstitial/parenchymal lung disease
I.q - Pulmonary nodulosis
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)
I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
IV.d IV - Airway involvement
IV.d - Cough (lone)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion
V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (may cause acute chest pain (see also under XIc)
V.n V - Pleural and/or pericardial involvement
V.n - Hemopericardium - Bloody pericardial effusion
V.s V - Pleural and/or pericardial involvement
V.s - Serositis - Polyserositis
VI.a VI - Pulmonary vasculopathies
VI.a - Venous thrombo-embolism - Pulmonary embolism
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VIII.a VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death)
VIII.aj VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.aj - Endobronchial lymphoproliferative disorder
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain (see also under Vi)
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)
XIII.g XIII - Neoplastic conditions
XIII.g - Lymphomatoid granulomatosis (pulmonary, endothoracic)
XIII.k XIII - Neoplastic conditions
XIII.k - Lymphoproliferative disease (extrathoracic)
XV.a XV - Pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.h XV - Pathology
XV.h - Path: Fibrotic NSIP pattern
XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells)
XV.w XV - Pathology
XV.w - Path: Pulmonary edema (see also II/IIa)
XV.bq XV - Pathology
XV.bq - Path: Lymphoproliferative disease, endothoracic
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVI.w XVI - Imaging
XVI.w - Imaging: Lung nodule or nodules
XVI.bc XVI - Imaging
XVI.bc - Imaging: Intrathoracic lymph node enlargement
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.d XVII - Infections & related conditions
XVII.d - Pneumocystis jiroveci pulmonary colonization
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection
XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
5

Mitomycin C

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified)
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.c II - Pulmonary edema - Acute lung injury - ARDS
II.c - ARDS and the hemolytic-uremic syndrome (HUS)
III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH)
VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension
VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease
VI.f VI - Pulmonary vasculopathies
VI.f - Hemolytic and uremic syndrome (HUS). See also under Xaf
VI.p VI - Pulmonary vasculopathies
VI.p - Angiomatoid pulmonary vasculopathy
VIII.c VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
XV.a XV - Pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells)
XV.ak XV - Pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD)
2

Radiation therapy (early effects)

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
I.ab I - Interstitial/parenchymal lung disease
I.ab - Radiation-induced lung injury (RILI)
I.ac I - Interstitial/parenchymal lung disease
I.ac - Acute radiation pneumonitis
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.h V - Pleural and/or pericardial involvement
V.h - Chylothorax
VIII.c VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
XV.a XV - Pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.h XV - Pathology
XV.h - Path: Fibrotic NSIP pattern
XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the chest on 18F-PET scan
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
3

Radiation therapy (medium term & late effects)

I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified)
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD
I.o I - Interstitial/parenchymal lung disease
I.o - Focal/localized area of pneumonitis/fibrosis
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE)
III.c III - Pulmonary/alveolar hemorrhage
III.c - Hemoptysis
IV.h IV - Airway involvement
IV.h - Large airway necrosis
IV.k IV - Airway involvement
IV.k - Bronchiectasis
IV.m IV - Airway involvement
IV.m - Bronchial stenosis/stricture
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.h V - Pleural and/or pericardial involvement
V.h - Chylothorax
V.l V - Pleural and/or pericardial involvement
V.l - Malignant pleural mesothelioma
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
V.t V - Pleural and/or pericardial involvement
V.t - The apical cap
VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease
VI.ab VI - Pulmonary vasculopathies
VI.ab - Pulmonary artery stenosis
VII.d VII - Mediastinal involvement
VII.d - Fibrosing mediastinitis
VII.i VII - Mediastinal involvement
VII.i - Mediastinitis
VII.j VII - Mediastinal involvement
VII.j - Compression of mediastinal structures/organs
VII.l VII - Mediastinal involvement
VII.l - Calcification of mediastinal lymph nodes
VIII.c VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.r VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.r - Tracheal necrosis, chondronecrosis, perforation
VIII.ab VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.ab - Tracheal/bronchial fistula
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
XI.g XI - Miscellaneous
XI.g - Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)
XI.h XI - Miscellaneous
XI.h - Esophageal pathology (erosion, ulcer, tear, rupture, fistula)
XI.i XI - Miscellaneous
XI.i - Esophageal toxicity
XI.p XI - Miscellaneous
XI.p - Chest deformity: platythorax
XI.v XI - Miscellaneous
XI.v - Rib fracture
XI.ax XI - Miscellaneous
XI.ax - Esophageal stenosis/stricture
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia/infarction - Coronary artery disease, acute
XII.k XII - Cardiovascular involvement / toxicity
XII.k - Pericardial thickening - Constrictive pericarditis
XII.o XII - Cardiovascular involvement / toxicity
XII.o - Coronary artery disease, chronic
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Conduction disorders - Heart block (bundle branch- or AV-)
XII.ad XII - Cardiovascular involvement / toxicity
XII.ad - Effusive-constrictive pericarditis
XII.ak XII - Cardiovascular involvement / toxicity
XII.ak - Late left ventricular dysfunction/failure
XII.an XII - Cardiovascular involvement / toxicity
XII.an - Pericardial calcification
XII.bc XII - Cardiovascular involvement / toxicity
XII.bc - Coarctation of the aorta (acquired)
XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer
XIII.d XIII - Neoplastic conditions
XIII.d - Malignant mesothelioma (pleural, pericardial)
XIII.e XIII - Neoplastic conditions
XIII.e - Breast cancer
XIII.j XIII - Neoplastic conditions
XIII.j - Pulmonary synovial sarcoma
XIII.l XIII - Neoplastic conditions
XIII.l - Chondrosarcoma
XIII.m XIII - Neoplastic conditions
XIII.m - Tumor of the heart
XV.l XV - Pathology
XV.l - Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodule or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.bi XVI - Imaging
XVI.bi - Imaging: Hyperlucent lung
XVI.bj XVI - Imaging
XVI.bj - Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)
3

Radiation therapy to the breast

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD
I.o I - Interstitial/parenchymal lung disease
I.o - Focal/localized area of pneumonitis/fibrosis
I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id)
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
I.z I - Interstitial/parenchymal lung disease
I.z - Areas of consolidation
V.t V - Pleural and/or pericardial involvement
V.t - The apical cap
XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.o XII - Cardiovascular involvement / toxicity
XII.o - Coronary artery disease, chronic
XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer
XIII.m XIII - Neoplastic conditions
XIII.m - Tumor of the heart
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XVI.i XVI - Imaging
XVI.i - Imaging: An area or areas of involvement with a recognizable anatomic distribution
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
2

Radiation therapy to the chest

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified)
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.o I - Interstitial/parenchymal lung disease
I.o - Focal/localized area of pneumonitis/fibrosis
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.h III - Pulmonary/alveolar hemorrhage
III.h - Major/massive hemoptysis
IV.h IV - Airway involvement
IV.h - Large airway necrosis
IV.m IV - Airway involvement
IV.m - Bronchial stenosis/stricture
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.h V - Pleural and/or pericardial involvement
V.h - Chylothorax
V.k V - Pleural and/or pericardial involvement
V.k - Pleural calcifications
VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease
VI.x VI - Pulmonary vasculopathies
VI.x - Pulmonary lymphangiectasis
VII.d VII - Mediastinal involvement
VII.d - Fibrosing mediastinitis
VIII.c VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.r VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.r - Tracheal necrosis, chondronecrosis, perforation
VIII.t VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.t - Vocal cord paralysis
VIII.ab VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.ab - Tracheal/bronchial fistula
IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XI.h XI - Miscellaneous
XI.h - Esophageal pathology (erosion, ulcer, tear, rupture, fistula)
XI.i XI - Miscellaneous
XI.i - Esophageal toxicity
XI.j XI - Miscellaneous
XI.j - Esophageal dysmotility
XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases
XI.ag XI - Miscellaneous
XI.ag - Vertebral compression fracture
XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction
XII.k XII - Cardiovascular involvement / toxicity
XII.k - Pericardial thickening - Constrictive pericarditis
XII.o XII - Cardiovascular involvement / toxicity
XII.o - Coronary artery disease, chronic
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Conduction disorders - Heart block (bundle branch- or AV-)
XIII.e XIII - Neoplastic conditions
XIII.e - Breast cancer
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.h XV - Pathology
XV.h - Path: Fibrotic NSIP pattern
XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells)
XV.bm XV - Pathology
XV.bm - Path: Diffuse lymphangiectasis
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.af XVII - Infections & related conditions
XVII.af - Reactivation of a prior pulmonary infection (TB, melioidosis)
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
3

Radiocontrast media (RCM)

I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.j I - Interstitial/parenchymal lung disease
I.j - Lipoid pneumonia, exogenous
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.h II - Pulmonary edema - Acute lung injury - ARDS
II.h - Overload pulmonary edema (including posttransfusional (TACO))
II.i II - Pulmonary edema - Acute lung injury - ARDS
II.i - Flash (fulminate) pulmonary edema
III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
IV.b IV - Airway involvement
IV.b - Bronchospasm and angioedema
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
VI.e VI - Pulmonary vasculopathies
VI.e - Fat/oil embolism - The FES embolism syndrome
VI.aa VI - Pulmonary vasculopathies
VI.aa - Lipiodol pulmonary embolism
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis
X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reactions (may involve skin, throat and/or airways)
X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS)
X.ap X - Systemic/Distant conditions, syndromes and reactions
X.ap - Delayed anaphylaxis
XVIII.h XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.h - Eye-catcher: Lipiodol embolism
1

Rituximab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified)
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.i II - Pulmonary edema - Acute lung injury - ARDS
II.i - Flash (fulminate) pulmonary edema
III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH)
III.c III - Pulmonary/alveolar hemorrhage
III.c - Hemoptysis
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (see also IVn)
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
IV.j IV - Airway involvement
IV.j - Bronchiolitis (a clinical-imaging pattern suggestive of)
IV.k IV - Airway involvement
IV.k - Bronchiectasis
VII.g VII - Mediastinal involvement
VII.g - Hemomediastinum - Mediastinal hematoma
VIII.x VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.x - Opportunistic large airway infection (bacterial, fungal, viral)
IX.t IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.t - CNS involvement/dysfunction/damage
IX.ab IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ab - Guillain-Barré (or GB-like) syndrome (w/wo ARF)
X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis
X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reactions (may involve skin, throat and/or airways)
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS)
X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary/systemic (ANCA-positive)
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia/infarction - Coronary artery disease, acute
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.j XV - Pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern)
XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.m XVII - Infections & related conditions
XVII.m - Fungal airway infection
XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia
XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency
1